Having established that the combination of the increased and persistent intracellular dose of DOX delivered by a CD133 aptamer and inhibition of autophagy resulted in enhanced apoptosis of liver cancer stem cells, we proceeded to evaluate if such a favorable pharmacological and pharmacodynamic effect could translate into the therapeutic outcome of eliminating liver cancer stem cells. This evidence concerns the gene PROM1 and liver cancer.